SLC5A2 and type 2 diabetes mellitus: Clinical studies have shown that the combination of metformin with SGLT2 inhibitors can further reduce blood glucose concentrations before and after fasting in patients with clinical T2DM, as well as increase glucose-to-creatinine ratio and promote weight loss (16).